Product-related factors and immunogenicity of biotherapeutics

M Krishna - Journal of Pharmaceutical Innovation, 2020 - Springer
… There have been several excellent reviews on this subject, … glycan structures on
biopharmaceutical products is especially … been made to standardize nomenclature and …

Harmonization and standardization of immunogenicity assessment of biotherapeutic products

M Wadhwa, R Thorpe - Bioanalysis, 2019 - Future Science
interpretation of the product's immunogenicity and its clinical effects. Efforts are ongoing to
standardize … Broadly, both the EMA and FDA guidelines are aligned and well-harmonized with …

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

A Ducret, C Ackaert, J Bessa, C Bunce, T Hickling… - MAbs, 2022 - Taylor & Francis
… the European Immunogenicity Platform (EIP) reviews currently … and next steps toward
harmonization and standardization. … interpretation and translation into an overall immunogenicity

Communicating Immunogenicity-Associated Risk in Current US FDA Prescription Drug Labeling: A Systematic Evaluation

D Guinn, R Madabushi, YM Wang, E Brodsky… - Therapeutic Innovation …, 2020 - Springer
… current guidance recommendations for immunogenicity content … by standardizing
immunogenicity-related terminology and … Future work understanding past evaluation practices and …

Effective presentation of immunogenicity risk assessments and related data in regulatory dossiers

P Chamberlain - Bioanalysis, 2019 - Future Science
… application for novel biopharmaceutical products in ICH … other regulatory guidelines provide
recommendations for … population can preclude a full understanding of the nature of the risks …

When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform

GP Lotz, K Benstein, K Bloem, H Buddiger… - The AAPS journal, 2022 - Springer
… However, there is no common understanding in which cases … In recent years, concepts for
the initial risk assessment have … is recommended in case of high risk of immunogenicity) until …

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

…, M Pallardy, P Broët, ABIRISK consortium - … medicine, 2020 - journals.plos.org
… from the Innovative Medicines Initiative Joint Undertaking under … recommendations used by
the pharmaceutical industry [6]. … encoded to standardized terms with the MedDRA dictionary, …

Nonclinical immunogenicity risk assessment of therapeutic proteins

S Tourdot, TP Hickling - Bioanalysis, 2019 - Future Science
… Regulatory agencies have issued specific guidelines to therapeutic protein immunogenicity
… the terms and definitions for data interpretation in the field of unwanted immunogenicity was …

[HTML][HTML] The innovative medicines initiative− 10 years of public-private collaboration

H Laverty, P Meulien - Frontiers in medicine, 2019 - frontiersin.org
initiatives and is attempting to strengthen the understanding of … in some cases they even
suggest ideas to be considered for … 10 consortium has produced a set of recommendations for …

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis

…, P Broët, X Mariette, ABIRISK Consortium - Seminars in Arthritis and …, 2019 - Elsevier
… , standardized and uploaded into the ABIRISK (Anti-Biopharmaceutical Immunization: …
P Dönnes reports grants from Innovative Medicines Initiative Joint Undertaking during the …